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Regulation of articular cell metabolism by CTAP mediators 
By C. William Castor, Terrence D. Fremuth, Dedra J. Roberts, M. Charlene Bignali, and Paul A. 
Hossler; University of Michigan, Arthritis Unit, Ann Arbor, Michigan 
S TUDY of human osteoarthritic chondrocytes in cell culture provides an opportunity to examine 
factors affecting qualitative and quantitative aspects 
of proteoglycan synthesis. We have been interested in 
characteristics and actions of autacoid mediators and 
drugs capable of regulating proteoglycan synthesis in 
vitro. Basic ideas arising in the course of this work are 
shown in Fig. I. “Connective tissue activation” results 
from the actions of autacoid mediators, derived in 
large part from leucocytes or platelets, which induce 
increased metabolic activity (activation) in connective 
tissue cells. The activating substances are peptides, 
which we have termed “connective tissue activating 
peptides” or CTAP. They have been found in lympho- 
cytes,’ tumor cells, platelets,2a and polymorphonu- 
clear leucocytes.5 CTAP-I, -II, and -III have been 
purified to homogeneity and their amino acid compo- 
sition is known. CTAP-III, from platelets, has been 
studied further; its sequence is now known and an 
RIA is available. CTAP-P,, is a second platelet- 
derived mediator recently identified in outdated 
human platelets6 
Dose-response curves testing CTAP-I and CTAP- 
111 against human synovial cell strains show essen- 
tially linear dose-response kinetics (Fig. 2). Incremen- 
tal isotopic incorporation was shown by enzymatic 
techniques to be almost entirely hyaluronic acid when 
synovial cell strains were target cultures. When “?Z- 
glucosamine was used as a precursor for GAG synthe- 
sis in two osteoarthritic human chondrocyte straings, 
CTAP-I, CTAP-III, and CTAP-PZ all caused 
substantial increments in ‘?Z-GAG formation. Addi- 
tion of a /3-xyloside had little apparent effect on 
incorporation of glucosamine except when added in 
the presence of cycloheximide. Cycloheximide mark- 
edly reduced the incorporation of glucosamine into 
GAG, presumably due to inhibiting synthesis of the 
protein core. inhibition of GAG synthesis was 
reversed when fi-xyloside was added. Cortisol caused 
approximately 50% inhibition in glucosamine incorpo- 
ration in basal cultures as well as a marked reduction 
in the stimulatory effects brought about by the media- 
tors. 
Stimulation by CTAP mediators and @-xyloside can 
be identified (Table 1) by using 3550, as a precursor. 
lndomethacin modestly reduced stimulated incorpo- 
ration of sulfate into sulfated GAG. The combined 
effects of CTAP mediators and @-xyloside were some- 
what greater than would be expected if they were 
merely additive. 
The “C-glucosamine and sulfate-labeled GAG 
from chondrocyte cultures were chromatographed 
over Sephacryl S-300 columns, and a large void 
volume peak was shown by enzymatic analysis to be 
largely hyaluronic acid with a small amount of chon- 
droitin 4/6 sulfate (CS-4/6). When the cultures 
included a ,9-xyloside, the void volume component was 
markedly reduced and a substantial peak developed in 
the retarded volume. The large peak in the internal 
volume was shown enzymatically to be primarily CS- 
Fig. 1. Connective tissue “activation.” 
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0.15M N&l 14,014 + 1,016 
0.15MNaCl + 10-3MDTE 14,824 + 1,575 
CTAP-I (10.6 rg/ml) 20,240 f 1,940 
CTAP-III (10.1 pg/ml) 28,600 i 6,670 
CTAP-P, (82 pg/ml) 29,198 f 5,276 
Poly I:Poly c (50 pg/ml) 17,450 + 4,589 
Insulin (10 Fg/mll 14,428 f 1,417 
@-Xyloside ( 100 pg/ml) 43,921 + 3,036 
CTAP-I + &Xyloside 58,432 ‘- 2,534 
CTAP-III + P-Xyloside 84,889 -t 3,551 
CTAP-P, + P-Xyloside 82,056 5 7,005 
Insulin + fl-Xyloside 53,055 k 5.663 
lndomethacin (15 rg/ml) 14,476 i 854 
CTAP-I + lndocin 17,248 i 1,896 














CTAP-P, + lndocin 23,998 + 2,873 71%: 
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Fig. 2. Dose-response curve. 
416. Sulfate-labeled GAG showed, in the absence of 
@xyloside, a small peak of radiolabeled material of 
large molecular weight appearing in the void volume, 
which was essentially CS-4/6. With P-xyloside in the 
incubation mixture, a striking increase in labeled 
product occurred, which was the lower molecular 
weight CS-4/6 expected in the internal volume of the 
column. 
The composition of 14C-GAG synthesized by 
human chondrocytes in the presence of various test 
materials was examined, and it was noted that corti- 
sol, indomethacin, and acetylsalicylic acid in clinically 
relevant concentrations had somewhat different 
effects on the qualitative composition of these glycos- 
aminoglycans. Cortisol and indomethacin appeared to 
have a disproportionately greater effect in reducing 
hyaluronic acid formation, whereas this selective 
effect appeared less marked with aspirin. It is interest- 
ing to note that CTAP-I, -111 and -P2, all of which 
cause quantitative increase in GAG synthesis, 
appeared to retain the relative proportions of GAG 
seen in control cultures. 
In summary, we believe that the quantitative 
aspects of proteoglycan synthesis are potentially easily 
subject to modulation by stimulatory and inhibitory 
factors in the microenvironment of the chondrocytes, 
and would anticipate that further work will show that 
the qualitative characteristics relating to the chemical 
anatomy of proteoglycan aggregates will in a similar 
manner be subject to modification at the time of 
synthesis. 
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